U.S. pharma giant copyright scrapped two experimental weight loss drugs past year—a at the time-everyday tablet, lotiglipron, due to elevated liver enzymes as well as a twice-day by day capsule, danuglipron, because of powerful Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Perform and win” in the